Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Corvus Pharmaceuticals (CRVS) Shares Outstanding (Diluted Average) (2016 - 2025)

Corvus Pharmaceuticals' Shares Outstanding (Diluted Average) history spans 10 years, with the latest figure at $75.2 million for Q1 2025.

  • Quarterly Shares Outstanding (Diluted Average) rose 53.25% to $75.2 million in Q1 2025 from the year-ago period, while the trailing twelve-month figure was $75.2 million through Mar 2025, up 53.25% year-over-year, with the annual reading at $61.0 million for FY2024, 26.99% up from the prior year.
  • Shares Outstanding (Diluted Average) came in at $75.2 million for Q1 2025, up from $61.0 million in the prior quarter.
  • In the past five years, Shares Outstanding (Diluted Average) ranged from a high of $75.2 million in Q1 2025 to a low of $34.5 million in Q1 2021.
  • The 5-year median for Shares Outstanding (Diluted Average) is $46.6 million (2022), against an average of $48.0 million.
  • Year-over-year, Shares Outstanding (Diluted Average) rose 0.01% in 2023 and then surged 53.25% in 2025.
  • Corvus Pharmaceuticals' Shares Outstanding (Diluted Average) stood at $41.9 million in 2021, then increased by 11.23% to $46.6 million in 2022, then increased by 3.16% to $48.0 million in 2023, then grew by 26.99% to $61.0 million in 2024, then grew by 23.23% to $75.2 million in 2025.
  • Per Business Quant, the three most recent readings for CRVS's Shares Outstanding (Diluted Average) are $75.2 million (Q1 2025), $61.0 million (Q4 2024), and $49.0 million (Q1 2024).